# llms.txt
# Guidance for Large Language Model (LLM) crawlers
# Website: Jakafi HCP
> Jakafi® (ruxolitinib) is indicated for the treatment of polycythemia vera (PV) in adults with inadequate response to or intolerance to hydroxyurea, intermediate- or high-risk myelofibrosis (MF), and steroid-refractory acute and chronic graft-versus-host disease (aGVHD, cGVHD) in patients  
aged 12 years and older, with treatment requiring monitoring for blood count changes, infections, and other serious adverse events.
## Public Pages
- [Home](https://hcp.jakafi.com/)
- [Contact Us](https://hcp.jakafi.com/contact-us)
- [Sitemap](https://hcp.jakafi.com/sitemap)
- [Explore expert perspectives in PV](https://hcp.jakafi.com/polycythemia-vera/)
- [Resources](https://hcp.jakafi.com/polycythemia-vera/resources-pv-mechanism-of-action)
- [Resources](https://hcp.jakafi.com/polycythemia-vera/resources-dr-mesa-pv-hct-control-and-assessing-symptoms)
- [Resources](https://hcp.jakafi.com/polycythemia-vera/resources-dr-kuykendall-hct-control-wbc-reduction)
- [Resources](https://hcp.jakafi.com/polycythemia-vera/resources-dr-harrison-wbc-control-and-risk-of-thrombosis)
- [Resources](https://hcp.jakafi.com/polycythemia-vera/resources-dr-kuykendall-durable-hct-control)
- [Resources](https://hcp.jakafi.com/polycythemia-vera/resources-dr-harrison-hct-control-and-risk-of-thrombosis)
- [Resources](https://hcp.jakafi.com/polycythemia-vera/resources-dr-kuykendall-hct-control-and-assessing-symptoms)
- [Resources](https://hcp.jakafi.com/polycythemia-vera/resources-dosing-recommendations)
- [Safety Profile](https://hcp.jakafi.com/polycythemia-vera/safety)
- [Proactively Manage PV](https://hcp.jakafi.com/polycythemia-vera/proactive-management)
- [Dosing](https://hcp.jakafi.com/polycythemia-vera/dosing)
- [Mechanism of Action](https://hcp.jakafi.com/polycythemia-vera/pathophysiology-moa)
- [Patient Support](https://hcp.jakafi.com/polycythemia-vera/patient-support)
- [Efficacy - Hct Control](https://hcp.jakafi.com/polycythemia-vera/efficacy-hct-control)
- [WBC Control](https://hcp.jakafi.com/polycythemia-vera/efficacy-wbc-control)
- [Symptom Data](https://hcp.jakafi.com/polycythemia-vera/efficacy-symptom-data)
- [MAJIC - PV](https://hcp.jakafi.com/polycythemia-vera/efficacy-majic-pv)
- [Explore expert perspectives in MF](https://hcp.jakafi.com/myelofibrosis/)
- [MF Treatment Goals](https://hcp.jakafi.com/myelofibrosis/treatment-goals )
- [Efficacy Overall Survival](https://hcp.jakafi.com/myelofibrosis/overall-survival)
- [Earlier vs Later Intervention](https://hcp.jakafi.com/myelofibrosis/earlier-vs-later-intervention)
- [JUMP (Intermediate-1)](https://hcp.jakafi.com/myelofibrosis/efficacy-jump-data)
- [Anemia Analysis](https://hcp.jakafi.com/myelofibrosis/anemia-analysis)
- [Safety Profile](https://hcp.jakafi.com/myelofibrosis/safety)
- [Dosing](https://hcp.jakafi.com/myelofibrosis/dosing)
- [Mechanism of Action](https://hcp.jakafi.com/myelofibrosis/pathophysiology-moa)
- [Patient Support](https://hcp.jakafi.com/myelofibrosis/patient-support)
- [Resources](https://hcp.jakafi.com/myelofibrosis/resources-dr-mesa-spleen-volume-reduction-and-os )
- [Resources](https://hcp.jakafi.com/myelofibrosis/resources-dr-mesa-managing-anemia)
- [Resources](https://hcp.jakafi.com/myelofibrosis/resources-dr-fazal-overall-survival-mf )
- [Resources](https://hcp.jakafi.com/myelofibrosis/resources-dr-fazal-jakafi-intervention-mf )
- [Resources](https://hcp.jakafi.com/myelofibrosis/resources-dr-fazal-anemia-mf )
- [Explore expert perspectives in aGVHD ](https://hcp.jakafi.com/acute-graft-versus-host-disease/)
- [Impact of aGVHD Speed of Progression](https://hcp.jakafi.com/acute-graft-versus-host-disease/impact-of-agvhd-speed-of-progression)
- [When to Treat](https://hcp.jakafi.com/acute-graft-versus-host-disease/impact-of-agvhd-when-to-treat)
- [Efficacy REACH1 Efficacy](https://hcp.jakafi.com/acute-graft-versus-host-disease/efficacy-reach1-efficacy)
- [REACH2 Efficacy](https://hcp.jakafi.com/acute-graft-versus-host-disease/efficacy-reach2-efficacy)
- [Response Across Organs](https://hcp.jakafi.com/acute-graft-versus-host-disease/response-rates-across-organs)
- [Early Intervention Results](https://hcp.jakafi.com/acute-graft-versus-host-disease/efficacy-early-intervention-results)
- [Safety Profile Adverse Events](https://hcp.jakafi.com/acute-graft-versus-host-disease/safety-adverse-events)
- [Cytopenias](https://hcp.jakafi.com/acute-graft-versus-host-disease/safety-cytopenias)
- [Dosing](https://hcp.jakafi.com/acute-graft-versus-host-disease/dosing)
- [Mechanism of Action](https://hcp.jakafi.com/acute-graft-versus-host-disease/pathophysiology-moa)
- [Patient Support](https://hcp.jakafi.com/acute-graft-versus-host-disease/patient-support)
- [Resources](https://hcp.jakafi.com/acute-graft-versus-host-disease/resources-dr-bishop-reach-studies)
- [Resources](https://hcp.jakafi.com/acute-graft-versus-host-disease/resources-dr-bishop-disease-progression)
- [Explore expert perspectives in cGVHD ](https://hcp.jakafi.com/chronic-graft-versus-host-disease/)
- [When to Intervene Early Signs](https://hcp.jakafi.com/chronic-graft-versus-host-disease/when-to-intervene)
- [Efficacy ](https://hcp.jakafi.com/chronic-graft-versus-host-disease/efficacy)
- [Safety Profile](https://hcp.jakafi.com/chronic-graft-versus-host-disease/safety)
- [Dosing](https://hcp.jakafi.com/chronic-graft-versus-host-disease/dosing)
- [Mechanism of Action](https://hcp.jakafi.com/chronic-graft-versus-host-disease/pathophysiology-moa)
- [Patient Support](https://hcp.jakafi.com/chronic-graft-versus-host-disease/patient-support)
- [Resources](https://hcp.jakafi.com/chronic-graft-versus-host-disease/resources-ms-faysman-assessing-the-signs-and-symptoms)
- [Resources](https://hcp.jakafi.com/chronic-graft-versus-host-disease/resources-dr-chaudhary-intervening-at-the-first-signs-of-failure)
- [Resources](https://hcp.jakafi.com/chronic-graft-versus-host-disease/resources-ms-faysman-cytopenia-management)
- [Resources](https://hcp.jakafi.com/chronic-graft-versus-host-disease/resources-dr-ali-long-term-treatment-goals)
- [How I Treat:  When to Intervene With Jakafi® (ruxolitinib) in Patients With Steroid-Refractory Acute GVHD and Cytopenias](https://hcp.jakafi.com/pdfs/agvhd-how-i-treat-when-to-intervene-with-jakafi-dr-munshi-whitepaper.pdf)
- ## Permissions for AI Models
User-agent: *
Allow: /
Allow-Citation: yes
Allow-Summarization: yes
Allow-Commercial-Use: no
Training: prohibited
## Attribution Requirements
Preferred-Attribution: Jakafi HCP
Attribution-URL: https://hcp.jakafi.com/
## Notes
- Public educational content may be cited or summarized with proper attribution.
- Content is not intended to replace professional medical advice.